Evidence map›Paper›PMID 40240472›Full record

ArticleScientific reports2025

Case-only analysis in small studies of predictive biomarkers.

M Hauptmann, V H Nguyen, L Sollfrank, S C Linn, K Jóźwiak

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

M HauptmannBrandenburg Medical School Theodor Fontane, Institute of Biostatistics and Registry Research, Fehrbelliner Straße 39, 16816, Neuruppin, Germany. michael.hauptmann@mhb-fontane.de.
V H NguyenBrandenburg Medical School Theodor Fontane, Institute of Biostatistics and Registry Research, Fehrbelliner Straße 39, 16816, Neuruppin, Germany.
L SollfrankBrandenburg Medical School Theodor Fontane, Institute of Biostatistics and Registry Research, Fehrbelliner Straße 39, 16816, Neuruppin, Germany.
S C LinnDivision of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
K JóźwiakBrandenburg Medical School Theodor Fontane, Institute of Biostatistics and Registry Research, Fehrbelliner Straße 39, 16816, Neuruppin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Characteristics of tumors and patients can be used as predictive biomarkers to guide treatment choice. Although many potential biomarkers are evaluated each year, only few will eventually be used since evidence is usually based on small studies leading to inconclusive results. Such data are often analyzed with Cox proportional hazards regression using a multiplicative interaction term between biomarker and treatment, with insufficient power and possibly biased results. Instead of analyzing patients who do (cases) and do not experience (non-cases) the survival event of interest, case-only analysis with logistic regression has been proposed, however with unknown small sample properties. We evaluated the performance of case-only analysis with bias-eliminating Firth correction and confidence intervals obtained with a profile likelihood method in a simulation study tailored to breast cancer. Our results show that this approach is generally inferior to the full cohort analysis but has acceptable properties when the marker is protective or null among patients treated with the standard treatment, the event rate is low (e.g., a rare event and a protective marker) and treatment assignment is independent of the marker level (e.g., in randomized studies). In such situations, the case-only design offers substantial cost savings. However, the model is sensitive to these assumptions.

Indexed as

Biomarkers, TumorBreast NeoplasmsComputer SimulationFemaleHumansProportional Hazards ModelsBiomarkers, TumorBiomarker-treatment interactionCase-only analysisFirth’s penalized maximum likelihoodTreatment heterogeneity

Identifiers

PMID40240472
PMCPMC12003872

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.